Mayne Pharma, a Salisbury South, Australia-headquartered contract development and manufacturing organization and drug delivery technology company, has acquired the rights to the fentanyl transdermal delivery system (TDS), 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, and 100 mcg/hr from Par Pharmaceutical, the Chestnut Ridge, New York-based subsidiary of Endo International.

Fentanyl TDS is an AB-rated generic equivalent to Janssen Pharmaceuticals’ Duragesic (fentanyl), indicated for managing pain in opioid-tolerant patients severe enough to require daily treatment. Fentanyl TDS was developed by Corium, a commercial-stage biopharmaceutical company headquartered in Menlo Park, California that is focused on the development and manufacture of transdermal and transmucosal delivery systems.

Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium and has acquired select inventory as well as the rights to market the product in the US. The annual market sales for the fentanyl patch were approximately $560 million for the 12 months ending December 31, 2016, according to IMS Health (now QuintilesIMS) and as cited by Mayne Pharma.

Source: Mayne Pharma